Those first steps

AI points to life-saving therapy for newborn babies

In a special collaboration with medical and academic institutions in the region, SogetiLabs is supporting Assistance Publique–Hôpitaux de Paris and Raymond Poincaré University Hospital in the Global MovementS project, in developing a screening tool for spinal muscular atrophy (SMA) in infants using computer vision and artificial intelligence.

SMA is a rare neuromuscular disorder that has a life-threating prognosis for newborns if gone undetected. The good news: if detected early, it can be treated with gene therapy and supportive care.

With AI technology, clinicians are now able to identify abnormal mobility more quickly, with 97% accuracy, and at a younger age than is usually considered for such diagnoses. For a challenging diagnosis such as SMA, this technology could become a critical procedural step necessary to mobilize resources and counsel families through the therapy process in time. If deployed on a national level, it could save the lives of 1 in 2,000 babies born with this disease.

sogeti
Part of Capgemini